Pulse Biosciences (NASDAQ:PLSE) Trading Down 4.1% – Here’s What Happened

Pulse Biosciences, Inc. (NASDAQ:PLSE) fell 4.1% on Monday . The stock traded as low as $15.23 and last traded at $15.13. 60,225 shares were traded during trading, a decline of 65% from the average session volume of 172,022 shares. The stock had previously closed at $15.77.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Pulse Biosciences to a “sell” rating in a report on Monday, March 31st.

Pulse Biosciences Trading Down 2.8%

The stock’s 50-day moving average is $16.99 and its 200 day moving average is $17.91.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Thursday, May 8th. The company reported ($0.25) earnings per share for the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Pulse Biosciences by 15.1% during the fourth quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company’s stock worth $19,958,000 after purchasing an additional 150,506 shares during the period. Bank of America Corp DE boosted its holdings in shares of Pulse Biosciences by 0.4% during the 4th quarter. Bank of America Corp DE now owns 788,454 shares of the company’s stock worth $13,727,000 after buying an additional 2,884 shares during the period. Geode Capital Management LLC grew its stake in Pulse Biosciences by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 460,768 shares of the company’s stock valued at $8,024,000 after buying an additional 3,603 shares during the last quarter. Invesco Ltd. raised its holdings in Pulse Biosciences by 1,956.7% in the 4th quarter. Invesco Ltd. now owns 214,490 shares of the company’s stock worth $3,734,000 after acquiring an additional 204,061 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Pulse Biosciences by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company’s stock worth $2,598,000 after acquiring an additional 1,092 shares during the last quarter. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.